Argenx (Belgium)

Recent papers from Argenx (Belgium)

1. Determining the minimal important difference of EQ-5D-5 L utility values in CIDP patients using data from a large clinical trialQuality of Life Research · 2026
2. Maternal delivery of a MuSK agonist antibody reveals a novel strategy for understanding and treating early-onset neuromuscular diseasesNeurobiology of Disease · 2026
3. Understanding the Evidence Gaps in the Epidemiology and Burden of Lupus Nephritis and Membranous Nephropathy: A Targeted Literature ReviewJournal of health economics and outcomes research · 2026
4. Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE studyHaematologica · 2026
5. Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+)Frontiers in Neurology · 2026
6. Effect of efgartigimod IV on immature platelet fraction in primary immune thrombocytopenia in the ADVANCE IV trialBritish Journal of Haematology · 2026
7. The CD70/CD27 Axis in Tyrosine Kinase Inhibitor-Treated Chronic Phase Chronic Myeloid Leukemia Cells Is Not an Achilles HeelHematology Reports · 2026
8. Impact of fatigue and disability on health-related quality of life in CIDP: Results from an international surveyClinical Neurology and Neurosurgery · 2026
9. WRIB poster award winners 2026Bioanalysis · 2026
10. Assessing efgartigimod dosing patterns and Myasthenia Gravis Activities of Daily Living outcomes in clinical practice: results from a large patient support program databaseFrontiers in Neurology · 2026
11. Clinical efficacy and cost per improved outcome of treatments for generalized myasthenia gravis: evidence from a network meta-analysis and cost-per-responder analysisCurrent Medical Research and Opinion · 2026
12. Industrialization of Bayesian decision-making for proof-of-commercial-concept study designsJournal of Biopharmaceutical Statistics · 2026
13. Long‐Term Safety and Efficacy of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE / ADHERE + Trial Interim AnalysisJournal of the Peripheral Nervous System · 2026
14. Assessing Efgartigimod (VYVGART™) Social Media Posts in Generalized Myasthenia Gravis to Understand Patient, Caregiver, and Health Care Professional SentimentsNeurology and Therapy · 2026
15. TNFAIP3/A20 dysfunction drives innate and sterile hyperinflammationFrontiers in Immunology · 2026
16. Anti-C2–mediated complement inhibition prevents disease in a rat passive transfer model of myasthenia gravisJournal of Translational Autoimmunity · 2026
17. Optimization of the Cell‐Based Assay Methodology to Study Degradation of Acetylcholine Receptors (Antigenic Modulation) by Antibodies From Myasthenia Gravis PatientsMuscle & Nerve · 2026
18. Healthcare utilization and productivity losses associated with CIDP: results from an international surveyFrontiers in Neurology · 2026
19. US commercial health plan use of corticosteroids in step therapy protocols: Frequency and clinical appropriatenessJournal of Managed Care & Specialty Pharmacy · 2026
20. Real-world Effectiveness and Use of Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE REAL Study Design (P6-9.011)Neurology · 2026